<DOC>
	<DOCNO>NCT02938546</DOCNO>
	<brief_summary>The subject go use 18F-FDG PET/CT ass different genetic NSCLC metabolism cisplatin chemotherapy target therapy , define assessment criterion role 18F-FDG PET/CT NSCLC treatment respone last build multi-centre clinical trial platform molecular classification molecular imaging cancer chemotherapy assessment .</brief_summary>
	<brief_title>18F-FDG Metabolism Imaging Monitoring Non-small Cell Lung Cancer Curative Effect Chemotherapy Multicenter Clinical Study</brief_title>
	<detailed_description>Non-small-cell lung cancer ( NSCLC ) first lead cause cancer death world . Systemic chemotherapy contribute choice 50 % NSCLC patient . The genetic abnormality lead different therapy response chemotherapy scheme NSCLC patient . At present , early assessment prediction key optimize NSCLC therapy . 18F-FDG PET/CT noninvasive cell metabolism reaction molecular image technology ass cancer glucose metabolism sensitively react cancer proliferation degree . Hence 18F-FDG PET/CT may use assess NSCLC therapy response noninvasively . It reliable method individualize NSCLC treatment clinically define appropriate metabolism response cut-off value assess time point 18F-FDG PET/CT predict different genetic NSCLC patients.The subject go use 18F-FDG PET/CT ass different genetic NSCLC metabolism cisplatin chemotherapy target therapy , define assessment criterion role 18F-FDG PET/CT NSCLC treatment respone last build multi-centre clinical trial platform molecular classification molecular imaging cancer chemotherapy assessment .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Fluorodeoxyglucose F18</mesh_term>
	<criteria>pathological biopsy NSCLC ; stage IIIIV ; plan palliative chemotherapy ( neoadjuvant chemotherapy , convention target therapy ) due unable surgery ; radiation therapy chemotherapy 6 month enrollment ; predictive survival time half year ; diabetes chest radiotherapy chronic disease ; brain metastases patient ; secondary primary maligmant cancer 5 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>Non-small-cell lung cancer</keyword>
	<keyword>18F-FDG PET/CT</keyword>
	<keyword>treatment response assessment</keyword>
</DOC>